Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04854304
Other study ID # 844978
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 23, 2021
Est. completion date July 13, 2025

Study information

Verified date July 2023
Source Abramson Cancer Center at Penn Medicine
Contact Jessica Nunez
Phone 215-746-6788
Email Jessica.Nunez@pennmedicine.upenn.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

500 patients will be prospectively recruited to undergo a fast breast MRI examination. The women will be recruited for the study will meet the following criteria: 1. African American 2. negative DBT examination 11 months prior to recruitment 3. Heterogeneously and Extremely breast densities 4. clinically asymptomatic- no palpable masses, focal thickening or clinically significant discharge. Investigators will identify these patients EPIC database utilizing the date of their last mammogram. Interested patients may contact our research coordinators by the phone number provided in the recruitment materials. The study recruitment information will also be shared with referring physicians. Physicians may also directly refer patients to the study.


Description:

500 patients will be prospectively recruited to undergo an abbreviated or "FAST" breast MRI examination. The women will be recruited for the study must meet the following criteria: 1. African American 2. negative DBT examination no more than 11 months prior to the FAST MR 3. Heterogeneously and Extremely breast densities as graded on their most recent mammogram 4. clinically asymptomatic- no palpable masses, focal thickening or clinically significant nipple discharge. Investigators will identify these women via the EPIC database utilizing the date of their last mammogram. Interested women may contact our research coordinators by the phone number provided in the recruitment materials. The study recruitment information will also be shared with referring physicians. Physicians may also directly refer patients to the study.


Recruitment information / eligibility

Status Recruiting
Enrollment 500
Est. completion date July 13, 2025
Est. primary completion date July 13, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria: 1. African American female 2. Negative DBT examination within eleven months prior to recruitment 3. Heterogeneoulsy and Extremely breast densities 4. Clinically asymptomatic- no palpable masses or focal thickening, etc. Exclusion Criteria: 1. Patients who are pregnant and lactating 2. Patient who have not had a mammogram (DBT) in the past 11months 3. Patients who are unwilling or unable to provide written informed consent 4. Patients symptomatic for breast disease (e.g. experiencing discharge, lumps, ect.) 5. Recent breast surgery in the past 2 years including breast enhancements (e.g. implants or injections) 6. Patients who are unable to received an MRI with Gadolinium contrast 7. Patients who have not had an MRI of the breast with the past year

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Fast Breast Abbreviated Magnetic Renounce Imaging
Fast Breast MRI Imaging

Locations

Country Name City State
United States UPENN Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Abramson Cancer Center at Penn Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Breast cancer detection and false negative rates of supplemental screening with AB-MR The cancer detection and false negative rate (per 1000 women screened) of supplemental screening with AB-MR in this population will be measured as well as the stage, grade and subtype of detected and non-detected breast cancers. Through the completion of study, an average of 4 year
Primary Additional screening outcomes The rates of false positive exams prompting biopsy and short term follow-up recommendations after AB-MR will be evaluated. Through the completion of study, an average of 4 year
Secondary The screening outcomes of AB-MR in this population of Black women will be compared to a similar population of Caucasian women undergoing AB-MR. The cancer detection, false negative and false positive rates as well as stage and subtypes of cancers will be compared to a similar population of Caucasian women screened with AB-MR Through the completion of study, an average of 4 year
See also
  Status Clinical Trial Phase
Recruiting NCT01678170 - Clinical Application of Breast Blood-oxygen Functional Imaging Technology N/A
Completed NCT00039780 - Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel Phase 3
Completed NCT02909452 - Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04535466 - Diagnosis Predictive Modle for Dense Density Breast Tissue Based on Radiomics
Recruiting NCT01917279 - Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC Phase 3
Recruiting NCT01427400 - The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction Phase 4
Completed NCT05665894 - Vacuum-Assisted Evacuation (VAE) Of Symptomatic and/or Voluminous Breast Haematomas Following Surgeries And Percutaneous Procedures: a Retrospective Analysis
Not yet recruiting NCT04088110 - Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer Phase 2
Terminated NCT02997540 - Effect of Body Position and Probe Position on the Localization of Breast Mass
Terminated NCT01140776 - Clinical Evaluation of OSNA Breast Cancer System in Breast Cancer Patients Receiving Neoadjuvant Therapy N/A
Recruiting NCT04911101 - Performance Indicators and Patient Experience in 7G and 10G Vacuum-assisted Excision of Probably Benign Breast Lesions N/A
Completed NCT04554316 - Aesthetic Effect of Steri-Strip Orientation on Healing and Scar Appearance in Breast Surgery N/A
Suspended NCT04151368 - Surgical and Patient Reported Outcomes of Robotic Nipple-Sparing Mastectomy N/A
Completed NCT03743259 - To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions Phase 2
Recruiting NCT04605575 - Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer Phase 2
Recruiting NCT05814224 - Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA N/A
Completed NCT02452333 - Oncoplastic Approach to Excisional Breast Biopsies N/A
Terminated NCT01372215 - Multi-Compression Spot Mammography N/A
Completed NCT00299039 - T3AI-Pain After Breast Surgery Phase 3
Active, not recruiting NCT05441943 - Lymphaticovenous Anastomosis as Treatment for Lymphedema N/A